CSS
SRPT icon

Cubist Systematic Strategies’s Sarepta Therapeutics SRPT Stock Holding History

Cubist Systematic Strategies’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,803
Closed -$888K – 3524
2025
Q2 		$852K Buy
+49,803
New +$2.12M ﹤0.01% 2025
2024
Q3 		– Sell
-148,114
Closed -$23.4M – 3472
2024
Q2 		$23.4M Buy
148,114
+54,500
+58% +$7M 0.16% 126
2024
Q1 		$12.1M Buy
93,614
+48,552
+108% +$5.95M 0.07% 398
2023
Q4 		$4.35M Buy
45,062
+26,643
+145% +$2.56M 0.03% 960
2023
Q3 		$2.23M Sell
18,419
-64,910
-78% -$7.34M 0.02% 1294
2023
Q2 		$9.54M Sell
83,329
-14,897
-15% -$1.92M 0.06% 457
2023
Q1 		$13.5M Sell
98,226
-41,141
-30% -$5.34M 0.08% 302
2022
Q4 		$18.1M Sell
139,367
-62,530
-31% -$7.25M 0.11% 187
2022
Q3 		$22.3M Buy
201,897
+99,935
+98% +$10.1M 0.13% 123
2022
Q2 		$7.64M Buy
101,962
+39,209
+62% +$2.88M 0.05% 637
2022
Q1 		$4.9M Sell
62,753
-38,900
-38% -$2.98M 0.04% 748
2021
Q4 		$9.15M Buy
101,653
+33,928
+50% +$2.9M 0.09% 286
2021
Q3 		$6.26M Buy
67,725
+10,665
+19% +$821K 0.08% 350
2021
Q2 		$4.44M Sell
57,060
-39,442
-41% -$2.99M 0.05% 605
2021
Q1 		$7.19M Buy
96,502
+91,903
+1,998% +$8.48M 0.09% 286
2020
Q4 		$784K Sell
4,599
-28,194
-86% -$4.18M 0.01% 1528
2020
Q3 		$4.61M Buy
32,793
+26,807
+448% +$4.07M 0.07% 448
2020
Q2 		$960K Buy
+5,986
New +$815K 0.02% 1210
2020
Q1 		– Sell
-29,292
Closed -$3.78M – 2436
2019
Q4 		$3.78M Sell
29,292
-89,250
-75% -$9.01M 0.07% 415
2019
Q3 		$8.93M Buy
118,542
+112,134
+1,750% +$13.2M 0.18% 131
2019
Q2 		$974K Sell
6,408
-8,636
-57% -$1.05M 0.02% 1060
2019
Q1 		$1.79M Buy
15,044
+11,726
+353% +$1.51M 0.06% 491
2018
Q4 		$362K Buy
3,318
+1,630
+97% +$204K 0.02% 1153
2018
Q3 		$273K Sell
1,688
-6,112
-78% -$836K 0.01% 1230
2018
Q2 		$1.03M Buy
+7,800
New +$736K 0.05% 469
2018
Q1 		– Sell
-973
Closed -$54K – 2050
2017
Q4 		$54K Sell
973
-813
-46% -$43.1K ﹤0.01% 1772
2017
Q3 		$81K Sell
1,786
-2,814
-61% -$112K ﹤0.01% 1663
2017
Q2 		$155K Buy
4,600
+2,474
+116% +$80.6K 0.01% 1363
2017
Q1 		$63K Sell
2,126
-2,813
-57% -$87.1K ﹤0.01% 1453
2016
Q4 		$135K Buy
4,939
+4,665
+1,703% +$187K 0.01% 1405
2016
Q3 		$17K Hold
274
– – ﹤0.01% 1625
2016
Q2 		$5K Sell
274
-29,631
-99% -$549K ﹤0.01% 1671
2016
Q1 		$584K Buy
29,905
+25,011
+511% +$437K 0.03% 694
2015
Q4 		$189K Sell
4,894
-13,495
-73% -$438K 0.01% 1378
2015
Q3 		$590K Buy
18,389
+16,589
+922% +$563K 0.03% 863
2015
Q2 		$55K Buy
1,800
+905
+101% +$18.5K ﹤0.01% 1698
2015
Q1 		$12K Buy
+895
New +$11.9K ﹤0.01% 1827
2014
Q4 		– Sell
-2,174
Closed -$46K – 2039
2014
Q3 		$46K Sell
2,174
-1,628
-43% -$36.7K ﹤0.01% 1640
2014
Q2 		$113K Buy
+3,802
New +$120K 0.01% 1304

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cubist Systematic Strategies's SRPT Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 49,803 shares — an estimated $888K sold.

Cubist Systematic Strategies first reported a position in SRPT in Q2 2014 and held it in 39 quarters. The position peaked at $23.4M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 49,803 Sarepta Therapeutics shares in Q3 2025, an estimated $888K.
  • Cubist Systematic Strategies first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 39 quarters.
  • Cubist Systematic Strategies's Sarepta Therapeutics position peaked at $23.4M in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.